SCHEMBL6047263

SCHEMBL6047263

Nc1nc(/C=C/CNCC2CC2)cc2nc(-c3ccco3)nn12

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.49
ADORA1 P30542 2/20 0.46
ADORA2B P29275 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047264 1.00 ADORA2A (0.49) ADORA2AADORA1ADORA2B
SCHEMBL6047205 0.83 ADORA2A (0.58) ADORA2A
SCHEMBL6047207 0.83 ADORA2A (0.58) ADORA2A
SCHEMBL6047223 0.77 ADORA2A (0.64) ADORA2AADORA1ADORA2B
SCHEMBL6047201 0.73 ADORA2A (0.50) ADORA2AADORA1ADORA2B
SCHEMBL12612295 0.71 ADORA2A (0.68) ADORA2AADORA1ADORA2B
SCHEMBL5653322 0.71 ADORA2A (0.71) ADORA2AADORA1ADORA2B
SCHEMBL6047272 0.70 ADORA2A (0.64) ADORA2A
SCHEMBL6628284 0.70 ADORA2A (0.65) ADORA2AADORA1
SCHEMBL6047254 0.70 ADORA2A (0.54) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058320-A1 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-16 US disclosed
EP-1544200-A1 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058320-A1 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.